The clinical pathological analyses confirm that the CCL16-CCR1 axis has the capability to enhance the infiltration of M2 macrophages in the microenvironment of liver cancer, indicating that targeting the CCL16-CCR1 axis could be a promising therapeutic approach for liver cancer. Here, CCR1 is linked to liver cancer.